2026-05-30

ETH open interest +182.9% — OI surge

BTC open interest -37.7% — OI collapse

SOL open interest +234.0% — OI surge

ETH open interest -62.7% — OI collapse

SOL open interest -59.2% — OI collapse

BTC open interest -36.8% — OI collapse

USDC/USDT has $128.6M volume but only $884K liquidity — thin market, slippage risk

SOL open interest +233.8% — OI surge

ETH open interest +180.5% — OI surge

BTC open interest -37.4% — OI collapse

SOL open interest -59.3% — OI collapse

ETH open interest -62.4% — OI collapse

BTC open interest -48.3% — OI collapse

OSINT: New Options Activity Replay Tool Launched for Real‑Time Market Insight

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: CBO Warns US Debt Gap to Deepen, Revenues to Lag by 2031

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: Iranian missile strike injures US troops, damages MQ‑9 drones in Kuwait

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: Kazakhstan Volunteers to Accept Iran's Uranium Stockpile, IAEA Says

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Oil -1.73% — significant selloff

Gold +1.36% — significant rally

Oil -1.73% — significant selloff

Gold +1.36% — significant rally

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves VENCLEXTA (AbbVie) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

MSFT RSI 71.7 — overbought (crossed above 70)

MSFT RSI 71.7 — overbought (crossed above 70)

Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q1-2026: Missed consensus by 113.2% — EPS $-104.41 vs $-48.9668 estimate

Q2-2026: Beat consensus by 183.1% — EPS $437.38079 vs $154.5037 estimate

Q3-2026: Beat consensus by 30.3% — EPS $524.42805 vs $402.4668 estimate

Q4-2026: Beat consensus by 25.8% — EPS $737.77 vs $586.3999 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Beat consensus by 98.8% — EPS $-0.09 vs $-7.497 estimate

Missed consensus by 42.4% — EPS $-15.9 vs $-11.169 estimate

Missed consensus by 114.9% — EPS $-204.15 vs $-95.013 estimate

Missed consensus by 322.0% — EPS $-18.08 vs $-4.284 estimate

Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Q2-2026: Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Q2-2025: Beat consensus by 296.1% — EPS $0.02 vs $-0.0102 estimate

Q4-2025: Beat consensus by 296.1% — EPS $0.01 vs $-0.0051 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0051 estimate

Missed consensus by 17.6% — EPS $-0.02 vs $-0.017 estimate

Missed consensus by 59.6% — EPS $-2.36 vs $-1.479 estimate

Q1-2026: Missed consensus by 366.9% — EPS $-1 vs $-0.2142 estimate

Q3-2025: Missed consensus by 86.9% — EPS $-0.61 vs $-0.3264 estimate

Q4-2025: Missed consensus by 416.1% — EPS $-1.79 vs $-0.3468 estimate

Q1-2026: Missed consensus by 55.7% — EPS $-0.43 vs $-0.2761 estimate

Q2-2025: Missed consensus by 892.1% — EPS $-0.64 vs $0.0808 estimate

Q3-2025: Beat consensus by 59.7% — EPS $0.2 vs $0.1252 estimate

Missed consensus by 199.0% — EPS $-0.1 vs $0.101 estimate

Q1-2023: Beat consensus by 52.6% — EPS $-4.95 vs $-10.4535 estimate

Q1-2024: Missed consensus by 372.2% — EPS $-1.24 vs $-0.2626 estimate

Q4-2022: Beat consensus by 26.7% — EPS $-9 vs $-12.2715 estimate

Q2-2023: Beat consensus by 52.1% — EPS $-5.445 vs $-11.3625 estimate

Q1-2026: Missed consensus by 694.1% — EPS $-0.06 vs $0.0101 estimate

Q4-2025: Missed consensus by 937.1% — EPS $-0.55 vs $0.0657 estimate

Q3-2025: Missed consensus by 57.5% — EPS $0.02 vs $0.0471 estimate

Q2-2025: Missed consensus by 133.0% — EPS $-0.05 vs $0.1515 estimate

Missed consensus by 19.0% — EPS $0.37 vs $0.457 estimate

Missed consensus by 5.3% — EPS $0.27 vs $0.285 estimate

Missed consensus by 17.3% — EPS $0.21 vs $0.254 estimate

Q1-2026: Missed consensus by 10.5% — EPS $0.09 vs $0.1006 estimate

Q2-2025: Beat consensus by 52.7% — EPS $0.3 vs $0.1964 estimate

Q2-2025: Beat consensus by 30.7% — EPS $-0.41 vs $-0.5916 estimate

Missed consensus by 12.6% — EPS $-31 vs $-27.54 estimate

Missed consensus by 8.9% — EPS $-30 vs $-27.54 estimate

Missed consensus by 20.3% — EPS $-24.55 vs $-20.4 estimate

Beat consensus by 172.0% — EPS $0.34 vs $0.125 estimate

Q2-2025: Beat consensus by 16.6% — EPS $0.26 vs $0.2229 estimate

Q1-2026: Missed consensus by 135.7% — EPS $-0.04 vs $0.1122 estimate

Q4-2025: Missed consensus by 4017.6% — EPS $-0.91 vs $-0.0221 estimate

Q1-2026: Beat consensus by 14.1% — EPS $1.01 vs $0.8851 estimate

Q4-2025: Beat consensus by 13.4% — EPS $0.88 vs $0.7762 estimate

Q1-2026: Missed consensus by 98.0% — EPS $-0.02 vs $-0.0101 estimate

Q2-2025: Beat consensus by 50.5% — EPS $-0.01 vs $-0.0202 estimate

Q1-2026: Beat consensus by 100.0% — EPS $0 vs $-0.0101 estimate

Beat consensus by 34.8% — EPS $-0.5 vs $-0.767 estimate

Q1-2026: Missed consensus by 86.7% — EPS $-1.8307890000000002 vs $-0.9806 estimate

Q4-2025: Beat consensus by 220.5% — EPS $0.4 vs $-0.3319 estimate

Q3-2025: Beat consensus by 31.3% — EPS $0.28 vs $0.2132 estimate

Q1-2026: Beat consensus by 82.8% — EPS $0.23 vs $0.1258 estimate

Q4-2025: Beat consensus by 8.5% — EPS $0.24 vs $0.2213 estimate

Q2-2025: Beat consensus by 13.9% — EPS $0.11 vs $0.0966 estimate

Missed consensus by 10.8% — EPS $0.47 vs $0.527 estimate

Q4-2025: Beat consensus by 7.4% — EPS $0.49 vs $0.4563 estimate

Q2-2025: Beat consensus by 10.0% — EPS $0.59 vs $0.5365 estimate

Missed consensus by 5.6% — EPS $2.49 vs $2.637 estimate

Q1-2026: Beat consensus by 40.5% — EPS $-0.43 vs $-0.7222 estimate

Q3-2025: Beat consensus by 16.4% — EPS $-0.74 vs $-0.8854 estimate

Q4-2025: Missed consensus by 32.0% — EPS $-0.9 vs $-0.6818 estimate

Beat consensus by 15.3% — EPS $-0.91 vs $-1.074 estimate

Q4-2025: Beat consensus by 264.5% — EPS $0.26 vs $-0.1581 estimate

Q3-2025: Beat consensus by 1815.7% — EPS $0.7 vs $-0.0408 estimate

Q2-2025: Beat consensus by 295.5% — EPS $0.44 vs $-0.2251 estimate

Q1-2026: Missed consensus by 117.3% — EPS $-0.03 vs $0.1734 estimate

Q2-2025: Beat consensus by 5.1% — EPS $1.64 vs $1.5599 estimate

Beat consensus by 14.3% — EPS $1.16 vs $1.015 estimate

Q1-2026: Missed consensus by 186.7% — EPS $-0.32 vs $-0.1116 estimate

Q4-2025: Beat consensus by 85.4% — EPS $-0.09 vs $-0.6152 estimate

Q3-2025: Beat consensus by 88.6% — EPS $-0.08 vs $-0.7021 estimate

Q1-2026: Missed consensus by 117.5% — EPS $-1.71 vs $-0.7862 estimate

Q2-2025: Beat consensus by 44.2% — EPS $-0.41 vs $-0.7347 estimate

Q4-2025: Beat consensus by 42.3% — EPS $0.16 vs $0.1124 estimate

Q2-2025: Beat consensus by 96.5% — EPS $0.09 vs $0.0458 estimate

Q1-2026: Beat consensus by 13.9% — EPS $0.12 vs $0.1054 estimate

Q4-2025: Beat consensus by 147.7% — EPS $0.81 vs $-1.6968 estimate

Q2-2025: Missed consensus by 98.0% — EPS $-2.24 vs $-1.1312 estimate

Q1-2026: Beat consensus by 13.0% — EPS $-0.58 vs $-0.6666 estimate

Q3-2025: Beat consensus by 80.2% — EPS $-0.084 vs $-0.4242 estimate

Beat consensus by 132.7% — EPS $9.4 vs $4.04 estimate

Missed consensus by 31.0% — EPS $4.6 vs $6.666 estimate

Beat consensus by 22.8% — EPS $3.1 vs $2.525 estimate

Beat consensus by 14.0% — EPS $3.8 vs $3.333 estimate

Q4-2025: Missed consensus by 79.4% — EPS $0.3 vs $1.4581 estimate

Q1-2026: Beat consensus by 357.5% — EPS $0.35 vs $0.0765 estimate

Q3-2025: Missed consensus by 242.6% — EPS $-0.4 vs $0.2805 estimate

Q4-2025: Beat consensus by 131.0% — EPS $0.07 vs $0.0303 estimate

Q1-2026: Beat consensus by 15.5% — EPS $0.21 vs $0.1818 estimate

Q2-2025: Beat consensus by 81.8% — EPS $0.56 vs $0.3081 estimate

Beat consensus by 37.0% — EPS $-192000 vs $-304616 estimate

Q2-2025: Missed consensus by 26.0% — EPS $-0.176 vs $-0.1397 estimate

Q1-2026: Beat consensus by 15.1% — EPS $-0.2 vs $-0.2357 estimate

Q3-2025: Missed consensus by 94.8% — EPS $-0.31 vs $-0.1591 estimate

Q2-2025: Beat consensus by 21.6% — EPS $-3.47 vs $-4.4248 estimate

Beat consensus by 21.6% — EPS $-0.16 vs $-0.204 estimate

Q3-2025: Beat consensus by 26.1% — EPS $-0.69 vs $-0.9343 estimate

Q4-2025: Beat consensus by 37.9% — EPS $-0.22 vs $-0.3545 estimate

Q4-2025: Missed consensus by 260.4% — EPS $-9.59 vs $-2.6613 estimate

Q1-2026: Beat consensus by 87.4% — EPS $-0.18 vs $-1.4308 estimate

Q3-2025: Missed consensus by 118.8% — EPS $-2.63 vs $-1.2019 estimate

Q2-2025: Missed consensus by 146.1% — EPS $-0.38 vs $0.8248 estimate

Q2-2025: Beat consensus by 8.2% — EPS $1.54 vs $1.4227 estimate

Q3-2025: Beat consensus by 6.4% — EPS $1.66 vs $1.5607 estimate

Q3-2025: Beat consensus by 34.1% — EPS $1651 vs $1231.5127 estimate

Q4-2025: Missed consensus by 55.4% — EPS $402 vs $902.3548 estimate

Q1-2026: Missed consensus by 62.6% — EPS $774 vs $2069.9378 estimate